Search

Your search keyword '"Pastorello E"' showing total 421 results
Start Over Author "Pastorello E"
421 results on '"Pastorello E"'

5. PD-0071 SBRT for spine oligometastases: a multicenter retrospective study on behalf of AIRO

Author

Cuccia, F., primary, Pastorello, E., additional, Franzese, C., additional, Belgioia, L., additional, Bignardi, M., additional, Federico, M., additional, Figlia, V., additional, Giaj Levra, N., additional, Lucchini, R., additional, Satragno, C., additional, Ferrero, A., additional, La Vecchia, M., additional, Fazio, I., additional, Ferrera, G., additional, Alongi, F., additional, and Scorsetti, M., additional

Published
2023
Full Text
View/download PDF

7. Toxicity patterns and preliminary clinical outcomes of 1.5T MR-guided stereotactic body radiotherapy for prostate cancer

Author

Cuccia, F., primary, Figlia, V., additional, Rigo, M., additional, Mazzola, R., additional, Giaj Levra, N., additional, Nicosia, L., additional, Ricchetti, F., additional, Trapani, G., additional, Attinà, G., additional, Pastorello, E., additional, Vitale, C., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2022
Full Text
View/download PDF

11. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis

Author

Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas‐Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E.‐M., Schmidt‐Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017
Full Text
View/download PDF

13. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti‐inflammatory drug hypersensitivity

Author

Cortellini, G., Romano, A., Santucci, A., Barbaud, A., Bavbek, S., Bignardi, D., Blanca, M., Bonadonna, P., Costantino, M. T., Laguna, J. J., Lombardo, C., Losappio, L.M., Makowska, J., Nakonechna, A., Quercia, O., Pastorello, E. A., Patella, V., Terreehorst, I., Testi, S., Cernadas, J. R., Dionicio Elera, J., Lippolis, D., Voltolini, S., and Grosseto, D.

Published
2017
Full Text
View/download PDF

14. PD-0086 PSMA-PET guided stereotactic body radiotherapy for bone oligorecurrent prostate cancer

Author

Cuccia, F., primary, Mazzola, R., additional, Pastorello, E., additional, Ingrosso, G., additional, Franzese, C., additional, Scorsetti, M., additional, Figlia, V., additional, Giaj-Levra, N., additional, Nicosia, L., additional, Rigo, M., additional, Ricchetti, F., additional, Vitale, C., additional, Attinà, G., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2022
Full Text
View/download PDF

17. PD-0575 Toxicity and QoL report of 1.5T MR-guided SBRT for prostate cancer in the first 100 patients

Author

Cuccia, F., primary, Figlia, V., additional, Rigo, M., additional, Nicosia, L., additional, Mazzola, R., additional, Giaj-Levra, N., additional, Ricchetti, F., additional, Attinà, G., additional, Pastorello, E., additional, Vitale, C., additional, De Simone, A., additional, Gurrera, D., additional, Naccarato, S., additional, Sicignano, G., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2022
Full Text
View/download PDF

18. PO-1086 Head and neck cancer of unknown primary: recurrence pattern based on treatment volumes

Author

Guaineri, A., primary, Maddalo, M., additional, Buglione di Monale e Bastia, M., additional, Magrini, S.M., additional, Toraci, C., additional, Bossi, P., additional, Paderno, A., additional, Maroldi, R., additional, Ravanelli, M., additional, Piazza, C., additional, La Mattina, S., additional, Facheris, G., additional, Volpi, G., additional, Singh, N., additional, and Pastorello, E., additional

Published
2022
Full Text
View/download PDF

20. Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma

Author

Sposato B., Scalese M., Ricci A., Rogliani P., Paggiaro P., Migliorini M. G., Di Tomassi M., Olivieri C., Perrella A., Camiciottoli G., Maselli R., Pelaia G., Busceti M. T., Sabato E., Cagnazzo M. G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M. F., Berra A., Calabrese C., Stanziola A. A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E. A., Scibilia G., Vianello A., Marchi M. R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Scichilone N., Novelli F., Latorre M., Vergura L., Masieri S., Rosati Y., Milanese M., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G. E., Foschino Barbaro M. P., Sposato B., Scalese M., Ricci A., Rogliani P., Paggiaro P., Migliorini M.G., Di Tomassi M., Olivieri C., Perrella A., Camiciottoli G., Maselli R., Pelaia G., Busceti M.T., Sabato E., Cagnazzo M.G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M.F., Berra A., Calabrese C., Stanziola A.A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E.A., Scibilia G., Vianello A., Marchi M.R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Scichilone N., Novelli F., Latorre M., Vergura L., Masieri S., Rosati Y., Milanese M., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G.E., Foschino Barbaro M.P., Sposato, B., Scalese, M., Ricci, A., Rogliani, P., Paggiaro, P., Migliorini, M. G., Di Tomassi, M., Olivieri, C., Perrella, A., Camiciottoli, G., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, L., Ravazzi, A., Bucca, C., Caiaffa, M. F., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Cazzola, M., Segreti, A., Pastorello, E. A., Scibilia, G., Vianello, A., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Matucci, A., Vultaggio, A., Maggi, E., Maestrelli, P., Guarnieri, G., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Macchia, L., Bellia, V., Scichilone, N., Novelli, F., Latorre, M., Vergura, L., Masieri, S., Rosati, Y., Milanese, M., Folletti, I., Pio, R., Pio, A., Maccari, U., Maggiorelli, C., Scala, R., Vignale, L., Pulera, N., Carpagnano, G. E., Foschino Barbaro, M. P., and Et, Al

Subjects
Pulmonary and Respiratory Medicine, severe asthma, medicine.medical_specialty, medicine.drug_class, Severe asthma, Eosinophil, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Gastroenterology, Persistence (computer science), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Bronchodilator, allergic asthma, blood eosinophil, bronchodilator reversibility, lung function decline, severe asthma, salbutamol, Forced Expiratory Volume, medicine, Settore MED/10, Immunology and Allergy, Humans, 030212 general & internal medicine, Blood eosinophil, Lung, Genetics (clinical), Lung function, Bronchodilator Agent, allergic asthma, blood eosinophil, bronchodilator reversibility, lung function decline, salbutamol, bronchodilator agents, eosinophils, forced expiratory volume, humans, lung, airway obstruction, asthma, business.industry, Airway obstruction, medicine.disease, Asthma, Bronchodilator Agents, Airway Obstruction, Eosinophils, 030228 respiratory system, Salbutamol, Blood eosinophils, business, medicine.drug, Human
Abstract

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1>12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), whereas BE were higher (380 cells/µl [170–590]) in RAO+ compared to RAO− subjects (77% [64–88], p=0.0001, 81.8% [66.1–94.3], p=0.0001, 21[18–23], p=0.045 and 230 cells/µl [80–360], p=0.003). A negative relationship between SABA-induced FEV1% changes and pre-bronchodilator FEV1% (β=−0.551%; p=0.0001) and ACT (β=−0.059; p=0.038) was found. Conversely, post-treatment BE levels were positively related (β=145.565 cells/µl; p=0.003) to FEV1>12% increases. A rising trend of pre-/post-bronchodilator FEV1% in time was observed in RAO− subjects with BE300 cells/µl reaching lower values after more than 36months of step-5 treatment (59.6% [39.9–72.1] vs 74[66.5–89.2] of RAO+ individuals with BE300 cells/µl [p=0.009]). Conclusion: Persistent SABA-induced FEV1>12%, especially when associated to BE>300 cells/ml, may be a marker of accelerated lung function decline in severe asthmatics despite maximal step-5 treatment. The highest bronchodilation associated to the lowest BE levels should be the main goal of asthma treatment to prevent such decline.

Published
2020

21. PSMA-guided SBRT for bone oligometastatic prostate cancer: a monoinstitutional report of preliminary outcomes and toxicity

Author

Cuccia, F., primary, Mazzola, R., additional, Pastorello, E., additional, Rigo, M., additional, Giaj-Levra, N., additional, Nicosia, L., additional, Figlia, V., additional, Ricchetti, F., additional, Attinà, G., additional, Vitale, C., additional, De Simone, A., additional, Gurrera, D., additional, Naccarato, S., additional, Sicignano, G., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

22. Preliminary report of toxicity and quality of life of the first 100 patients treated with 1.5T MR-guided stereotactic body radiotherapy for prostate cancer

Author

Cuccia, F., primary, Figlia, V., additional, Rigo, M., additional, Nicosia, L., additional, Mazzola, R., additional, Giaj-Levra, N., additional, Ricchetti, F., additional, Attinà, G., additional, Pastorello, E., additional, De Simone, A., additional, Gurrera, D., additional, Naccarato, S., additional, Sicignano, G., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

23. Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intra-fraction motion during 1.5 t-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer

Author

Cuccia, F., primary, Mazzola, R., additional, Sicignano, G., additional, Vitale, C., additional, Rigo, M., additional, Giaj-Levra, N., additional, Nicosia, L., additional, Figlia, V., additional, Ricchetti, F., additional, Attinà, G., additional, Pastorello, E., additional, De Simone, A., additional, Gurrera, D., additional, Naccarato, S., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

24. PO-1439 Clinical results of SBRT for spinal metastases using dedicated contouring/planning system

Author

Figlia, V., primary, Giaj-Levra, N., additional, Mazzola, R., additional, Rigo, M., additional, Cuccia, F., additional, Nicosia, L., additional, Ricchetti, F., additional, Attinà, G., additional, Pastorello, E., additional, Sicignano, G., additional, De Simone, A., additional, Naccarato, S., additional, Gurrera, D., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

26. PO-1037 Hypofractionated Radiation Therapy For Non-Elderly Patients With Glioblastoma

Author

Tomasini, D., primary, Triggiani, L., additional, Pedretti, S., additional, Bonù, M.L., additional, Costa, L., additional, Pegurri, L., additional, Romano, L., additional, Singh, N., additional, Lamattina, S., additional, Pastorello, E., additional, Facheris, G., additional, Turla, O., additional, Borghetti, P., additional, Buglione Di Monale E Bastia, M., additional, and Magrini, S.M., additional

Published
2021
Full Text
View/download PDF

27. PO-1388 1.5 T MR-guided SBRT for oligorecurrent prostate cancer: preliminary report of feasibility and PROMs

Author

Cuccia, F., primary, Mazzola, R., additional, Figlia, V., additional, Rigo, M., additional, Nicosia, L., additional, Giaj-Levra, N., additional, Ricchetti, F., additional, Vitale, C., additional, Attinà, G., additional, Pastorello, E., additional, Di Paola, G., additional, De Simone, A., additional, Gurrera, D., additional, Naccarato, S., additional, Sicignano, G., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

28. PD-0863 Preliminary dosimetric report of 1.5-T MR-guided daily-adaptive SBRT for lymph-nodal oligometastases

Author

Cuccia, F., primary, Rigo, M., additional, Gurrera, D., additional, Nicosia, L., additional, Mazzola, R., additional, Figlia, V., additional, Giaj-Levra, N., additional, Ricchetti, F., additional, Attinà, G., additional, Pastorello, E., additional, De Simone, A., additional, Naccarato, S., additional, Sicignano, G., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

32. The diagnosis and management of allergic reactions in patients sensitized to non-specific lipid transfer proteins

Author

Skypala, I.J. Bartra, J. Ebo, D.G. Antje Faber, M. Fernández-Rivas, M. Gomez, F. Luengo, O. Till, S.J. Asero, R. Barber, D. Cecchi, L. Diaz Perales, A. Hoffmann-Sommergruber, K. Anna Pastorello, E. Swoboda, I. Konstantinopoulos, A.P. van Ree, R. Scala, E. European Academy of Allergy & Clinical Immunology (EAACI) Task Force: Non-specific Lipid Transfer Protein Allergy Across Europe

Abstract

Sensitization to one or more non-specific lipid transfer proteins (nsLTPs), initially thought to exist mainly in southern Europe, is becoming accepted as a cause of allergic reactions to plant foods across Europe and beyond. The peach nsLTP allergen Pru p 3 is a dominant sensitizing allergen and peaches a common food trigger, although multiple foods can be involved. A frequent feature of reactions is the requirement for a cofactor (exercise, alcohol, non-steroidal anti-inflammatory drugs, Cannabis sativa) to be present for a food to elicit a reaction. The variability in the food and cofactor triggers makes it essential to include an allergy-focused diet and clinical history in the diagnostic workup. Testing on suspected food triggers should also establish whether sensitization to nsLTP is present, using purified or recombinant nsLTP allergens such as Pru p 3. The avoidance of known trigger foods and advice on cofactors is currently the main management for this condition. Studies on immunotherapy are promising, but it is unknown whether such treatments will be useful in populations where Pru p 3 is not the primary sensitizing allergen. Future research should focus on the mechanisms of cofactors, improving diagnostic accuracy and establishing the efficacy of immunotherapy. © 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Published
2021

33. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

Author

Sposato, B, Scalese, M, Milanese, M, Masieri, S, Cavaliere, C, Latorre, M, Scichilone, N, Ricci, A, Cresti, A, Santus, P, Olivieri, C, Perrella, A, Rogliani, P, Paggiaro, P, Migliorini, M. G, Di Tomassi, M, Camiciottoli, G, Maselli, R, Pelaia, G, Busceti, M. T, Sabato, E, Cagnazzo, M. G, Colombo, F, Palumbo, L, Ravazzi, A, Bucca, C, Caiaffa, M. F, Berra, A, Calabrese, C, Stanziola, A. A, Schino, P, Di Gioacchino, M, Cazzola, M, Segreti, A, Pastorello, E. A, Scibilia, G, Vianello, A, Marchi, M. R, Paladini, L, Baglioni, S, Abbritti, M, Almerigogna, F, Matucci, A, Vultaggio, A, Maggi, E, Maestrelli, P, Guarnieri, G, Steinhilber, G, Bonavia, M, Rottoli, P, Bargagli, E, Senna, G, Caminati, M, Macchia, L, Bellia, V, Novelli, F, Vergura, L, Rosati, Y, Folletti, I, Pio, R, Pio, A, Maccari, U, Maggiorelli, C, Scala, R, Vignale, L, Pulerà, N, Carpagnano, G. E, Foschino Barbaro, M. P, The Omalizumab Italian Study Group, Sposato, B, Scalese, M, Milanese, M, Masieri, S., Cavaliere, C, Latorre, M., Scichilone, N., Ricci, A., Cresti, A., Santus, P., Olivieri, C., Perrella, A., Rogliani, P., Paggiaro, P., Sposato, B., Migliorini, M. G., Di Tomassi, M., Camiciottoli, G., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, L., Ravazzi, A., Bucca, C., Caiaffa, M. F., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Cazzola, M., Segreti, A., Pastorello, E. A., Scibilia, G., Vianello, A., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Matucci, A., Vultaggio, A., Maggi, E., Maestrelli, P., Guarnieri, G., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Macchia, L., Bellia, V., Novelli, F., Vergura, L., Scalese, M., Rosati, Y., Milanese, M., Folletti, I., Pio, R., Pio, A., Maccari, U., Maggiorelli, C., Scala, R., Vignale, L., Pulera, N., Carpagnano, G. E., Foschino Barbaro, M. P., Cavaliere, C., Sposato B., Scalese M., Milanese M., Masieri S., Cavaliere C., Latorre M., Scichilone N., Ricci A., Cresti A., Santus P., Olivieri C., Perrella A., Rogliani P., Paggiaro P., Migliorini M.G., Di Tomassi M., Camiciottoli G., Maselli R., Pelaia G., Busceti M.T., Sabato E., Cagnazzo M.G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M.F., Berra A., Calabrese C., Stanziola A.A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E.A., Scibilia G., Vianello A., Marchi M.R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Novelli F., Vergura L., Rosati Y., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G.E., and Foschino Barbaro M.P.

Subjects
Adult, Male, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Treatment outcome, MEDLINE, Omalizumab, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Immunoglobulin E, eosinophil, Omalizumab, anti-IgE, asthma, Leukocyte Count, Text mining, Forced Expiratory Volume, Internal medicine, Eosinophilia, medicine, Humans, Immunology and Allergy, Anti-Asthmatic Agents, Blood eosinophil, Aged, Retrospective Studies, Asthma, biology, business.industry, Retrospective cohort study, Middle Aged, asthma, Prognosis, medicine.disease, Eosinophils, Treatment Outcome, inflammation, biology.protein, Female, business, medicine.drug
Published
2019

34. Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients

Author

Asero, R, Abbadessa, S, Aruanno, A, Barilaro, G, Barzaghi, C, Bignardi, D, Bilò, M B, Borro, M, Bresciani, M, Busa, M, Buzzulini, F, Cavaliere, C, Cecchi, L, Ciccarelli, A, Cortellini, G, Cucinelli, F, Deleonardi, G, Emiliani, F, Farsi, A, Ferrarini, E, Franchini, M, Ingrassia, A, Lippolis, D, Losappio, L, Marra, A M, Martini, M, Masieri, S, Mauro, M, Mazzolini, M, Muratore, L, Murzilli, F, Nucera, E, Pastorello, E A, Pinter, E, Polillo, B R, Pravettoni, V, Quercia, O, Rizzi, A, Russello, M, Sacerdoti, C, Scala, E, Scala, G, Scarpa, A, Schroeder, J, Uasuf, G G, Villalta, D, Yang, B, Mistrello, G, Amato, S, Lidholm, J, Nucera, E (ORCID:0000-0002-0565-7680), Rizzi, A (ORCID:0000-0002-6795-746X), Asero, R, Abbadessa, S, Aruanno, A, Barilaro, G, Barzaghi, C, Bignardi, D, Bilò, M B, Borro, M, Bresciani, M, Busa, M, Buzzulini, F, Cavaliere, C, Cecchi, L, Ciccarelli, A, Cortellini, G, Cucinelli, F, Deleonardi, G, Emiliani, F, Farsi, A, Ferrarini, E, Franchini, M, Ingrassia, A, Lippolis, D, Losappio, L, Marra, A M, Martini, M, Masieri, S, Mauro, M, Mazzolini, M, Muratore, L, Murzilli, F, Nucera, E, Pastorello, E A, Pinter, E, Polillo, B R, Pravettoni, V, Quercia, O, Rizzi, A, Russello, M, Sacerdoti, C, Scala, E, Scala, G, Scarpa, A, Schroeder, J, Uasuf, G G, Villalta, D, Yang, B, Mistrello, G, Amato, S, Lidholm, J, Nucera, E (ORCID:0000-0002-0565-7680), and Rizzi, A (ORCID:0000-0002-6795-746X)

Abstract

Background: Peach gibberellin-regulated protein (peamaclein) has recently emerged as a relevant food allergen in cypress pollen-hypersensitive patients. Objective: We looked for mono-sensitization to peamaclein among Italian cypress-pollen allergic patients. Material and methods: 835 cypress pollen hypersensitive patients from 28 Italian allergy centers under went thorough interview for food-allergic reactions, and SPT with a commercial peach extracts containing peamaclein. In peach reactors, IgE to rPru p 3 was measured, and those scoring negative were enrolled as potentially mono-sensitized to peamaclein. IgE reactivity to rPru p 7 was evaluated by immunoblot and by an experimental ImmunoCAP with rPru p 7. Results: Peach SPT scored positive in 163 (19.5%) patients but 127 (77,9%) were excluded because Pru p 3 reactors. Twenty-four (14,7%, corresponding to 2.8% of the entire study population) were considered as potentially mono-sensitized to peamaclein. Their distribution did not show any geographic preference. Seventeen/24 (70,8%) had a history of food allergy, in most cases (n=15) to peach. Other offending foods included other Rosaceae, citrus fruits, fig, melon, tree nuts, and kiwi. On peach immunoblot, only 3/18 putative peamaclein allergic subjects reacted to a band at about 7kDa; 4 other patients reacted at about 50-60 kDa. Ten/18 (56%) scored positive for Pru p 7 on ImmunoCAP. Conclusion: Peamaclein allergy and sensitization prevalence seem rare in Italy. Most patients react to peach, albeit other Rosaceae fruits and several citrus fruits may also act as offending foods. Peach and cypress pollen probably share also cross-reacting allergens other than peamaclein.

Published
2020

35. Evaluation of two commercial peach extracts for skin prick testing in the diagnosis of hypersensitivity to lipid transfer protein. A multicenter study

Author

Asero, R, Aruanno, A, Bresciani, Marco Torkel, Brusca, I, Carollo, M, Cecchi, L, Cortellini, G, Deleonardi, G, Farsi, A, Ferrarini, E, Gabrielli, Francesca Augusta, Ingrassia, A, Mauro, M, Murzilli, F, Nucera, Eleonora, Onida, R, Pastorello, E A, Pinter, E, Rizzi, Angela, Russello, M, Sacerdoti, C, Scala, G, Villalta, D, Zampogna, S, Amato, S, Mistrello, G, Scala, E, Bresciani, M, Gabrielli, G, Nucera, E (ORCID:0000-0002-0565-7680), Rizzi, A (ORCID:0000-0002-6795-746X), Asero, R, Aruanno, A, Bresciani, Marco Torkel, Brusca, I, Carollo, M, Cecchi, L, Cortellini, G, Deleonardi, G, Farsi, A, Ferrarini, E, Gabrielli, Francesca Augusta, Ingrassia, A, Mauro, M, Murzilli, F, Nucera, Eleonora, Onida, R, Pastorello, E A, Pinter, E, Rizzi, Angela, Russello, M, Sacerdoti, C, Scala, G, Villalta, D, Zampogna, S, Amato, S, Mistrello, G, Scala, E, Bresciani, M, Gabrielli, G, Nucera, E (ORCID:0000-0002-0565-7680), and Rizzi, A (ORCID:0000-0002-6795-746X)

Abstract

The clinical usefulness of two commercial peach extracts for SPT (by Lofarma SpA and ALK-Abellò, respectively) was compared in a multicenter study carried out in Italy. Peach allergic patients were tested with the two extracts in parallel and underwent the detection of IgE specific for all three peach allergens currently available (Pru p 1, Pru p 3, and Pru p4, respectively). The two extracts were almost identical in terms of sensitivity and specificity, being able to detect virtually all patients sensitized to stable peach allergens (lipid transfer protein [LTP] and, presumably, peamaclein) but scoring negative in patients exclusively sensitive to labile allergens (either PR-10 and/or profilin). Thus, the two extracts represent an excellent tool to carry out a preliminary component-resolved diagnosis of peach allergy at the first patient visit

Published
2020

42. House dust mite allergy and shrimp allergy: a complex interaction

Author

Celi, G., primary, Brusca, I., additional, Scala, E., additional, Villalta, D., additional, Pastorello, E., additional, Farioli, L., additional, Cortellini, G., additional, Deleonardi, G., additional, Galati, P., additional, Losappio, L., additional, Manzotti, G., additional, Pirovano, B., additional, Muratore, L., additional, Murzilli, F., additional, Cucinelli, F., additional, Musarra, A., additional, Cilia, M., additional, Nucera, E., additional, Aruanno, A., additional, Ria, F., additional, Patria, M.F., additional, Varin, E., additional, Polillo, B.R., additional, Sargentini, V., additional, Quercia, O., additional, Uasuf, C.G., additional, Zampogna, S., additional, Carollo, M., additional, Graci, S., additional, and Asero, R., additional

Published
2020
Full Text
View/download PDF

50. Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients

Author

Schroeder, J, Folci, M, Losappio, L, Chevallard, M, Sinico, R, Mirone, C, De Luca, F, Nichelatti, M, Pastorello, E, Schroeder, Jan Walter, Folci, Marco, Losappio, Laura Michelina, Chevallard, Michel, Sinico, Renato Alberto, Mirone, Corrado, De Luca, Fabrizio, Nichelatti, Michele, Pastorello, Elide Anna, Schroeder, J, Folci, M, Losappio, L, Chevallard, M, Sinico, R, Mirone, C, De Luca, F, Nichelatti, M, Pastorello, E, Schroeder, Jan Walter, Folci, Marco, Losappio, Laura Michelina, Chevallard, Michel, Sinico, Renato Alberto, Mirone, Corrado, De Luca, Fabrizio, Nichelatti, Michele, and Pastorello, Elide Anna

Abstract

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with asthma, anti-neutrophil cytoplasmic antibodies (ANCA) positivity, and tissue eosinophilia. Objective: To describe the presenting clinical features, significant biochemical alterations, and also potential pathogenic factors in adult patients diagnosed in our Center over a period of >20 years. Method: A retrospective study of EGPA patients diagnosed from 1994 to 2019 at ASST Grande Ospedale Metropolitano Niguarda Ca' Granda, Milan (Italy), which was performed according to the 1990 American College of Rheumatology criteria and Chapel Hill Consensus Conference definition. A dataset was compiled, registering demographic and clinical features, biochemical analysis at onset, and also the therapies received 3 months prior to EGPA diagnose. Statistical analyses were subsequently conducted dividing patients in 2 groups based on ANCA positivity and comparing them. Results: Two groups were clearly identified by ANCA serology and specific organ involvement in accordance with literature reports; however, our data underline for the first time the association between anti-leukotriene receptor antagonists (LTRAs) and ANCA positivity. The group of previously treated patients presents an OR of 6.42 to be ANCA positive. This finding could be attributed to an imbalanced stimulation of leukotriene receptors, inducing both mast cells activation and an increased neutrophil extracellular traps release from neutrophils. Conclusion: Despite the limitations of this retrospective study, the association between LTRAs and ANCA antibodies elucidates the mechanism by which innate immunity is directly involved in tolerance breakdown and autoantibodies production. Validation of our results with targeted studies could clarify the differences between ANCA-positive and ANCA-negative patients with important consequences on the use of some drug classes in the treatment of EGPA and asthmatic subjects.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results